
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen Inc. is focusing on the promising therapeutic potential of its Wnt pathway modulators, which have demonstrated preclinical evidence of retinal vessel regrowth and the suppression of pathological vessel growth. The company's innovative product candidates, particularly the FZD4 bi-specific antibody, are positioned to lead advancements in treating complex conditions such as wet age-related macular degeneration and diabetic macular edema. Additionally, the continued validation of these drug candidates through their preclinical programs underscores the potential for significant long-term growth and value in the biotechnology sector.
Bears say
Surrozen Inc. is facing significant risks that contribute to a negative outlook on its stock, primarily due to the potential failure of its developmental candidates to meet peak commercial revenue estimates, which is influenced by factors such as market size and pricing strategies. Additionally, the company has reported a substantial net loss of $27.0 million, or $7.43 per diluted share for the first quarter of 2025, indicating financial strain and a lack of immediate profitability. Lastly, the ongoing need to secure adequate capital resources for operations and continued program development raises concerns about the company's ability to sustain its business model in the competitive biotechnology landscape.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares